Valuation: TG Therapeutics, Inc.

Market Cap 8.15B 7.15B 6.75B 6.15B 11.52B 781B 11.6B 80.79B 31.29B 399B 30.59B 29.92B 1,282B P/E 2026 *
60.7x
P/E 2027 * 20.1x
Enterprise Value 8.32B 7.3B 6.89B 6.28B 11.76B 797B 11.84B 82.47B 31.94B 407B 31.22B 30.55B 1,309B EV / Sales 2026 *
8.66x
EV / Sales 2027 * 5.92x
Free-Float
88.56%
Yield 2026 *
-
Yield 2027 * -
1 day-0.16%
1 week+0.98%
Current month+5.76%
1 month+3.63%
3 months+7.09%
6 months+80.48%
Current year+92.65%
1 week 54.78
Extreme 54.78
58.92
1 month 52.11
Extreme 52.11
58.92
Current year 26.76
Extreme 26.76
59.3
1 year 26.76
Extreme 26.76
59.3
3 years 6.46
Extreme 6.46
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 29/12/2011
Director of Finance/CFO 44 29/12/2011
Investor Relations Contact - 01/12/2011
Director TitleAgeSince
Chairman 60 29/12/2011
Director/Board Member 79 01/03/2012
Director/Board Member 62 09/11/2012
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/26 Sell

Director

-5,000 0.0033%
7/8/26 Don

Director

-950 0.0006%
28/1/26 Don

Director

43,197 0.0272%
Change 5-day change 1-year change 3-year change Capi.($)
-0.16%+0.98%+65.79%+539.53% 8.15B
+0.13%+2.65%+65.61%+114.28% 1,055B
+0.20%+0.46%+52.60%+69.24% 654B
-0.29%+0.14%+20.96%+70.93% 467B
-0.85%+0.98%+41.29%+44.38% 348B
+0.71%+4.08%+22.24%+29.51% 275B
+1.23%+0.42%+14.57%+12.13% 258B
+2.11%+7.51%+52.89%+55.37% 224B
+0.83%+0.55%+35.99%+101.70% 187B
0.00%-10.14%-29.94%-60.30% 171B
Average +0.31%+0.76%+34.20%+97.68% 364.65B
Weighted average by Cap. +0.02%+1.32%+41.59%+68.88%

Financials

2026 *2027 *
Net sales 960M 843M 796M 725M 1.36B 92.03B 1.37B 9.52B 3.69B 47.01B 3.6B 3.53B 151B 1.32B 1.16B 1.09B 995M 1.86B 126B 1.88B 13.07B 5.06B 64.54B 4.95B 4.84B 207B
Net income 157M 138M 130M 119M 223M 15.09B 224M 1.56B 605M 7.71B 591M 578M 24.77B 450M 395M 373M 340M 636M 43.14B 641M 4.46B 1.73B 22.04B 1.69B 1.65B 70.84B
Net Debt 169M 148M 140M 128M 239M 16.2B 241M 1.68B 649M 8.28B 635M 621M 26.6B -348M -305M -288M -263M -492M -33.35B -496M -3.45B -1.34B -17.04B -1.31B -1.28B -54.76B
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
25/09/26 US$57.43 -0.16% 1,308,925
24/09/26 US$57.52 +2.71% 1,138,354
23/09/26 US$56.00 -3.63% 2,119,983
22/09/26 US$58.11 +1.66% 2,084,660
21/09/26 US$57.16 +0.51% 2,142,757
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
57.43USD
Average target price
69.71USD
Spread / Average Target
+21.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock